1. Home
  2. PED vs CHRS Comparison

PED vs CHRS Comparison

Compare PED & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pedevco Corp.

PED

Pedevco Corp.

N/A

Current Price

$14.65

Market Cap

152.8M

Sector

Energy

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$1.37

Market Cap

177.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PED
CHRS
Founded
N/A
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.8M
177.7M
IPO Year
2012
2014

Fundamental Metrics

Financial Performance
Metric
PED
CHRS
Price
$14.65
$1.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$30.00
$5.51
AVG Volume (30 Days)
16.0K
1.1M
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
$45,751,000.00
N/A
Revenue This Year
$171.75
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
15.67
N/A
52 Week Low
$0.43
$1.09
52 Week High
$18.89
$2.62

Technical Indicators

Market Signals
Indicator
PED
CHRS
Relative Strength Index (RSI) 67.70 49.65
Support Level $14.12 $1.33
Resistance Level $16.70 $1.46
Average True Range (ATR) 0.63 0.08
MACD 0.16 0.01
Stochastic Oscillator 93.63 47.62

Price Performance

Historical Comparison
PED
CHRS

About PED Pedevco Corp.

PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: